Eric D. Shaff Receives Stock Award at Seres Therapeutics Inc (MCRB) — SEC Form 4, Jul 06, 2022
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Equity Position
96.3K sh
32,842 → 96,334
Equity Change
+193.3%
shares held after vs before
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Eric D. Shaff CIK 0001643734 |
Director
CEO
|
Eric D. Shaff at Seres Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$9,095
More from this insider at Seres Therapeutics Inc
| 2026-08-18 | Sell | -$1,197 | View |
| 2026-07-10 | Award | — | View |
| 2026-05-19 | Sell | -$1,950 | View |
| 2026-02-18 | Sell | -$2,194 | View |
| 2025-11-18 | Sell | -$3,754 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| COMMON STOCK | 2022-07-05 | A - Award/Grant | 63,492 A | $3.15 | +$200,000 | 96,334 | Direct |
Related filings at Seres Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
35
institutional managers reporting a position
Largest by reported value
- Flagship Pioneering Inc. $9.12M
- Vanguard Capital Management Llc $2.27M
- Marshall Wace, Llp $1.36M
Other insiders at Seres Therapeutics Inc
GET /v1/forms/4/0000899243-22-025509
API docs
View Original SEC Filing